Nuvalent
preliminary efficacy radiographic tumor regression observed across all dose levels | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
17 of 31
Related slides by other companies
AstraZeneca
Investor Event
September 2024
promising efficacy in heavily treated patients with ovarian breast and endometrial cancer sie | AstraZeneca
Morgan Stanley
Investment Banking
August 2022
orange comparable regression analysis | Morgan Stanley
Alkermes
Investor Day
March 2021
immune modulation portfolio of engineered technical challenge alkermes protein engineering solution key anti tumor mechanisms alfa tumor targeted split enhanced efficacy efficacy of limited by expansion of cells and other undesirable effects fusion of circularly permuted with the subunit resulting in only activating intermediate affinity has low tolerability when given systemically efficacy of limited by a protein that binds to separate inactive tumor targeted engineered for which activity is not subunits assemble and activate in the tumor blocked by suppressive mechanisms expansion of cells and cells minimal expansion of cells drive responses at the tumor site through potent activation of and cells enhance mediated anti cancer immune responses reduce cell exhaustion potential cancer types solid tumors including melanoma platinum resistant ovarian cancer solid tumors including pancreatic breast colon and ovarian cancer tumor inhibitor resistant tumors | Alkermes
Kymera
Results
December 2022
degradation profile of and in consistent with preclinical models in blood and tumor bent | Kymera
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights